Releases

Media coverage

Newsletter

Subscribe to our newsletter

Archive


Apr 7, 2014

Norsk tekst lenger ned

Øystein Rekdal is representing Lytix Biopharma at the American Association for Cancer Research (AACR) in San Diego April 5-9 2014. Leading scientists and a large number of pharmaceutical companies are attending, and the mission is to prevent and cure cancer through research, education, communication and collaboration. Lytix Biopharma is happy to announce that three poster presentations are accepted. All three will be presented on April 7 from 1.00PM to 5.00PM in Hall A-E, Poster Section 28.

Poster no 1: Complete and specific regression of disseminated tumors in a novel mesenchymal three tumor-rat model after intralesional treatment with the nonapeptide LTX-315 (OncoporeTM)
Poster Board number 19

Poster no 2: Complete Regression and Systemic Protective Immune Responses obtained in B16 Melanomas after Treatment with LTX-315 (Oncopore™)
Poster Board number 20

Poster no 3: In vitro cytotoxic activities of the membrane active nonapeptide LTX-315 (OncoporeTM) against human melanoma cells
Poster Board number 25

 

Norsk tekst

Øystein Rekdal representerer Lytix Biopharma på American Association for Cancer Research (AACR) i San Diego 5.-9. april - en av verdens største kreftkonferanser. Ledende forskere og et stort antall legemiddelselskaper deltar, og målet er å forebygge og helbrede kreft gjennom forskning, opplæring, kommunikasjon og samarbeid. Lytix Biopharma har fått akseptert tre posterpresentasjoner der nye og omfattende prekliniske resultater av selskapets ledende kreftmedikament LTX-315 presenteres.